Epigenetics leadership Oryzon Genomics is a clinical-stage biopharma leader in epigenetics with an established CNS and oncology/hematology focus, presenting a strong platform for partnerships around epigenetic therapies and biomarker-driven trials.

LSD1 pipeline Two differentiated LSD1 inhibitors, iadademstat and a CNS-focused program, are advancing in multiple Phase I–II fields with data readouts at major conferences, signaling active collaboration opportunities with pharma companies seeking targeted epigenetic approaches.

Biomarker leverage Robust biomarker platform supports precision medicine, enabling co-development discussions with collaborators to optimize patient stratification and potential companion diagnostics in CNS and oncology programs.

Strategic expansions Pipeline expansion into HDAC6 with ORY-4001 and exploration of neurological indications (ALS, CMT) create cross-therapy partnership potential and opportunities for joint R&D funding or licensing deals.

Strategic alliances Active engagement with international investors, regulatory advisors, and industry events (EHA, BIO) demonstrates readiness for partnerships, licensing deals, and sponsored research with global biopharma and life sciences entities.